1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors
US9475796B2 · kind B2 · utility
11Cited by
32References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 2012 |
| Grant date | Oct 25, 2016 |
| Priority date | — |
| Expiry date | Oct 3, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.